Lauren Sankary, JD, MA
Presented on Wednesday, January 19, 2022 – 4:00 PM MST
On June 7, 2021, the US Food and Drug Administration (FDA) approved aducanumab (Aduhelm; Biogen Inc), the first new drug for the treatment of Alzheimer disease in 2 decades. The approval of the drug, however, by FDA has not been without controversy and therefore, ethical challenges, as there are questions about its value. Lauren Sankary, JD, shares with us some of the ethical challenges that arise with this drug, and the state of FDA approvals.
Lauren Sankary is Associate Director of the Neuroethics Program, and Clinical Ethicist at Cleveland Clinic Neurological Institute, Department of Bioethics.